Repligen EPS misses by $0.01, beats on revenue

Repligen (NASDAQ:RGEN): Q2 Non-GAAP EPS of $0.31; GAAP EPS of $0.17 misses by $0.01.

Revenue of $70.69M (+48.1% Y/Y) beats by $5.22M.

Press Release

https://seekingalpha.com/news/3485210-repligen-eps-misses-0_01-beats-revenue

GlycoMimetics EPS misses by $0.01

GlycoMimetics (NASDAQ:GLYC): Q2 GAAP EPS of -$0.37 misses by $0.01.

Cash and equivalents of $184.2M

Press Release

https://seekingalpha.com/news/3485211-glycomimetics-eps-misses-0_01

Syros Pharmaceuticals EPS misses by $0.05, beats on revenue

Syros Pharmaceuticals (NASDAQ:SYRS): Q2 GAAP EPS of -$0.47 misses by $0.05.

Revenue of $0.46M (+21.1% Y/Y) beats by $0.03M.

Press Release

https://seekingalpha.com/news/3485218-syros-pharmaceuticals-eps-misses-0_05-beats-revenue

Bausch Health expands cash-pay prescription program at Walgreens

Bausch Health Companies (NYSE:BHC) has expanded its agreement with Walgreens (NYSE:WBC) that enables patients to access certain Ortho Dermatologics products for flat cash payments of $50 – 115. The program, launched in March, will now be available in more than 9,500 Walgreens pharmacies in the U.S.

https://seekingalpha.com/news/3485226-bausch-health-expands-cash-pay-prescription-program-walgreens

Premarket analyst action

Khiron Life Sciences (OTCQB:KHRNF) initiated with Speculative Buy rating at Alta.

AMAG Pharmaceuticals (NASDAQ:AMAG) initiated with Buy rating and $16 (94% upside) price target at H.C. Wainwright.

United Therapeutics (NASDAQ:UTHR) upgraded to Buy with a $106 (34% upside) price target at Ladenburg Thalmann. Upgraded to Hold with a $90 price target at Jefferies.

https://seekingalpha.com/news/3485247-wainwright-likes-amag-pharma-premarket-analyst-action

AmerisourceBergen up 2% premarket on Q2 beat; raised guidance

AmerisourceBergen (ABC) Q2 results: Revenues: $45,239.3M (+4.9%); Pharmaceutical Distribution Services: $43,527.6M (+4.7%).

Net Income: $302M (+9.5%); EPS: $1.43 (+14.4%); Non-GAAP Net Income: $371.7M (+9.1%); Non-GAAP EPS: $1.76 (+14.3%); CF Ops: $1,671.2M (+124.0%).

Fiscal 2019 Guidance: Non-GAAP EPS: $7.00 to $7.10 from $6.70 to $6.90; Adjusted FCF: $1.5B to $1.7B from $1.4B to $1.6B.

Shares are up 2% premarket.

Previously: AmerisourceBergen EPS beats by $0.14, beats on revenue (Aug. 1)

https://seekingalpha.com/news/3485288-amerisourcebergen-2-percent-premarket-q2-beat-raised-guidance

Clovis Q2 miss pressures shares, down 12% premarket

Clovis Oncology (NASDAQ:CLVS) Q2 results: Rubraca (rucaparib) sales up 39% to $33.0M.

Net loss: ($120.4M) (-19%).

Future milestones: Updated data from TRITON2 evaluating Rubraca in BRCA-mutant mCRPC to be submitted to FDA later this month and presented at ESMO in September. Supplemental U.S. marketing application on track for Q4. Phase 2 study of Rubraca + Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) in gastric cancer to launch in Q4.

2019 guidance: Revenue: $137M – 147M.

Shares are down 12% premarket on light volume.

Previously: Clovis Oncology EPS misses by $0.57, misses on revenue (Aug. 1)

https://seekingalpha.com/news/3485290-clovis-q2-miss-pressures-shares-12-percent-premarket